<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951141</url>
  </required_header>
  <id_info>
    <org_study_id>2017-003-D</org_study_id>
    <nct_id>NCT04951141</nct_id>
  </id_info>
  <brief_title>Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors</brief_title>
  <official_title>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective to study the safety and preliminary efficacy of intratumoral injection of CAR-T&#xD;
      cells in the treatment of advanced liver tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events attributed to the administration of the anti-GPC3 CAR-T cells</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hepatocellular Carcinoma , Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>anti-GPC3 CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-GPC3 CAR-T cells</intervention_name>
    <description>A single arm, open-label pilot study is designed to determine the safety and efficacy of anti-GPC3 CAR-T cells in patients with GPC3-positive advanced liver cancer.</description>
    <arm_group_label>anti-GPC3 CAR-T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  GPC3 expression was positive by histological examination;&#xD;
&#xD;
          -  18-69 years old;&#xD;
&#xD;
          -  The patients with advanced liver tumor who can not be operated and the effect of&#xD;
             chemotherapy is poor;&#xD;
&#xD;
          -  The patients who received traditional palliative therapy had an expected survival&#xD;
             period of more than 4 months;&#xD;
&#xD;
          -  Organ status allows clinical application.a. Creatinine &lt; 1.5mg/dl; b. Cardiac ejection&#xD;
             index &gt; 55%; c. Heme &gt; 9g / dl, bilirubin &lt; 2.0mg/dl;&#xD;
&#xD;
          -  No bleeding and coagulation disorders were found;&#xD;
&#xD;
          -  There was no allergy to contrast medium;&#xD;
&#xD;
          -  Contraception: contraceptive measures were taken during clinical application and&#xD;
             within 3 months after the last cells transfusion;&#xD;
&#xD;
          -  There is no other contraindication for lymphocyte collection;&#xD;
&#xD;
          -  Sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Patients need systemic steroids therapy;&#xD;
&#xD;
          -  At present, the treatment conditions are as follows : a. Within 30 days before the&#xD;
             collection of peripheral blood mononuclear cells,patiens were in other anti-tumor&#xD;
             clinical observation period; b. Patients have not recovered from the acute side&#xD;
             effects of previous treatment;&#xD;
&#xD;
          -  Patients received radiotherapy within 4 weeks after enrollment;&#xD;
&#xD;
          -  Patients received other cell modification therapy in the early stage;&#xD;
&#xD;
          -  In the screening stage, patients with lymphocyte transfection rate less than 5%, or T&#xD;
             cell culture can not expand (&lt; 5 times) patients;&#xD;
&#xD;
          -  Uncontrolled symptoms or other diseases include, but are not limited to, infection,&#xD;
             congestive heart failure, unstable angina pectoris, arrhythmia, psychosis, or limiting&#xD;
             the social environment that meets the requirements, or the researchers believe that&#xD;
             they may bring unpredictable risks;&#xD;
&#xD;
          -  Patients with severe acute allergic reactions;&#xD;
&#xD;
          -  Patients who participated in other clinical trials;&#xD;
&#xD;
          -  Researchers believe that patients are not suitable to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yin ying Lu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing 302 Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fei Wu</last_name>
    <phone>+8615801390058</phone>
    <email>wufei@immunochina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Fifth Medical Center of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yin ying Lu, M.D.</last_name>
      <email>luyinying1973@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

